JCB, Volume 8, Number 2, 2001 Editorial Vol.8 No. 2 (2001) Cell therapy - When will it deliver its promise? Iain Cubitt   Article Vol.8 No. 2 (2001) Dealing with uncertainties in the biotechnology industry: The use of real options reasoning Sven Remer Managers of biotechnology companies face great technological and market risks in making investment decisions. Traditional investment decision tools such as the discounted Article Vol.8 No. 2 (2001) Emerging issues in research tool licensing Brent Bersin This paper presents a brief examination of the current trends and issues in the licensing of patented research tools, as well as perspectives on 'reach through' licensing of research Article Vol.8 No. 2 (2001) Genetic testing services in Europe: Quality assurance and policy issues Jean-Jacques Cassiman The popular press is painting a picture of a future in which everyone has a detailed DNA profile of themselves drawn up. Such a vision of the future, however, is more scie Article Vol.8 No. 2 (2001) Legal protection for inventions, designs and other information Noel Byrne Information is capable of being the stuff of intellectual property and related non-proprietary rights if the correct steps are taken to attract legal protection to the information, t Article Vol.8 No. 2 (2001) Consolidation revisited Alan Williams In 1998, the author produced two papers that argued that consolidation was a necessary activity for biotechnology companies to pay greater attention to. Three years late Article Vol.8 No. 2 (2001) The legal and ethical considerations relating to the supply and use of human tissue for biomedical research: A UK perpective John Wilkinson Alder Hey Children's Hospital supplied parts of the thymus gland removed from young children during heart surgery to a pharmaceutical company. The circumstances raised Article Vol.8 No. 2 (2001) Mergers and acquisitions: A consideration of the drivers and hurdles Ian McBeath Mergers and acquisitions (M&A) are increasingly being included by biopharmaceutical companies within earlier stage strategies as a means of accelerating technology development an Legal and Regulatory Updates Vol.8 No. 2 (2001) Legal and regulatory update John Wilkinson Presents updates on legal and regulatory issues concerning biotechnology and the pharmaceuticals industry in Europe as of September 2001. Proposals of the European Commission for ch Legal and Regulatory Updates Vol.8 No. 2 (2001) EU Financial accounts reports David Citron Presents updates on the 2000 financial results of several biotechnology and pharmaceutical firms in Europe. Celltech Group Plc; ML Laboratories plc; Pharmagene plc. Legal and Regulatory Updates Vol.8 No. 2 (2001) US Financial accounts reports Glenn Crocker Presents financial reports from U.S.-based biotechnology and pharmaceutical companies. Celera Genomics Groups; IDEC Pharmaceuticals Corp. Book Review Vol.8 No. 2 (2001) Book Review: The Biotechnology Revolution in Global Agriculture: Invention, Innovation and Investment in the Canola Sector Jeremy Curnock Cook The Biotechnology Revolution in Global Agriculture: Invention, Innovation and Investment in the Canola SectorPeter W. B. Phillips and George G
